Elsulfavirine - Viriom

Drug Profile

Elsulfavirine - Viriom

Alternative Names: Elpida; elpivirine; R1206; RO 4970335; RO 5011500; VM 1500; VM 1500 LAI; VM 1500 Long acting injectable

Latest Information Update: 23 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Viriom
  • Class Acetamides; Antivirals; Nitriles; Small molecules; Sulfones
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered HIV infections

Most Recent Events

  • 17 Oct 2018 Viriom plans a phase I trial for HIV-I infections in October 2018 (NCT03709355)
  • 01 Oct 2018 Viriom initiates enrolment in a phase I trial for HIV-1-infections (In volunteers) in Russia (NCT03706898)
  • 19 Sep 2018 Viriom announces its intention to launch elsulfavirine in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top